Bank of Scotland Corporate is to provide AIM-listed IS Pharma with a facility worth £8m (€10m) to fund the company’s continued growth and acquisition plans.
IS Pharma is a late-stage pharmaceuticals and medical devices business in the specialist hospital medicine sector, with a current focus on critical care, neurology and oncology.
The Chester-based company recently acquired Swiss pharmaceuticals group, Speciality European Pharmaceuticals, for £9.25m.
IS Pharma, previously Maelor, adopted its new name following the acquisition, which has given it a new portfolio of specialist hospital pharmaceutical products.
Share this story